Next Generation Complement Therapeutics Market, 2022-2035: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre S

Next Generation Complement Therapeutics Market, 2022-2035: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. In addition, the complement inhibitor drug, EMPAVELITM (pegcetacoplan), which is the first approved complement C3 inhibitor, developed by Apellis Pharmaceuticals, has been approved by the FDA for the treatment of paroxysmal nocturnal hemoglobinuria; it is believed to bring in new possibilities for the treatment of autoimmune and inflammatory disorders. Discovered in 19th century, complement system is a part of innate immune system and tissue homeostasis, which recognizes, tags and helps to eliminate various disease-causing pathogens. In addition, complement system plays a role in the physiology of a healthy organism (homeostasis) for the removal of apoptotic cells, thereby regulating cell survival. However, inadequate complement activation results in outgrowth of pathogens and suppression of complement regulators, which ultimately becomes a disease cause. As a result, complement-targeted therapeutics have been developed; they inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.

Several drug developers are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. A variety of molecules, such as biologics, gene therapies, oligonucleotides, small interfering RNAs and small molecule-based complement therapeutics are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders. Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future. Moreover, the R&D efforts in this field are also being supported by the National Institutes of Health, which have awarded grants worth USD 837 million for research efforts in this domain over the last few years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of the complement therapeutics is likely to expand. Further, with the encouraging clinical research efforts, broadening of disease focus and efforts to go beyond C5 with innovative approaches that could decrease prices and address safety concerns, the complement therapeutics market is poised to witness steady growth over the coming years.

SCOPE OF THE REPORT
The ‘Next Generation Complement Therapeutics Market, 2022-2035: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the next generation complement therapeutics in the treatment of various complement-mediated diseases. The study underlines an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain. Amongst other elements, the report includes:
A detailed review of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), type of drug, biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous), type of therapy (monotherapy and combination therapy) and dosing frequency. In addition, it includes a list of next generation complement therapeutics with special designations. Further, the chapter presents a list of players developing next generation complement therapeutics along with information on their year of establishment, company size and location of headquarters.
Detailed profiles of key players engaged in the development of next generation complement therapeutics (shortlisted on the basis of company size). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.
An in-depth analysis of completed, ongoing and planned clinical studies of various next generation complement therapeutics, highlighting prevalent trends across different parameters, such as current trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, study design, leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, type of drug, emerging focus areas and regional distribution of trials.
A detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, which have been published during 2017-2021, based on parameters, such as year of publication, emerging focus areas, top authors, key research journals, popular indication(s) and therapeutic area(s).
An in-depth analysis of grants awarded to various research institutes for the projects related to next generation complement therapeutics, during period 2017-2021, on the basis of parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section, type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.
An insightful analysis of the patents filed / granted for next generation complement therapeutics, between 2016- 2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.
An analysis of the partnerships that have been established in this domain since 2014, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, product distribution and commercialization agreement, research and development agreement, and research, development and commercialization agreement and other relevant types of deals.
A detailed analysis of the various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.
An analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

One of the key objectives of the report was to identify the primary growth drivers and estimate the future growth opportunity associated with next generation complement therapeutics market in the mid to long term. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the likely evolution of the market for the period 2022-2035.

Our year wise projections of the current and forecasted opportunity within the next generation complement therapeutics market have further been segmented across [A] Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), [B] Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), [C] Type of Molecule (Biologics and Small Molecules), [D] Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), [E] Type of Therapy (Monotherapy and Combination Therapy), [F] Route of Administration (Intravenous, Oral and Subcutaneous), [G] Key Geographical Regions (North America, Europe and Asia-Pacific. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various non-commercial trends emerging in the industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED
Who are the leading industry and non-industry players engaged in the development of next generation complement therapeutics?
Which are the key drugs being developed across early and late stages of development?
Which geographies are the most active in conducting clinical trials related to next generation complement therapeutics?
What is the focus area of various publications related to the next generation complement therapeutics?
Which are the leading funding institutes / centers supporting the research related to next generation complement therapeutics?
What kind of partnership models are commonly adopted by industry stakeholders?
Who are the key investors, active in the field of next generation complement therapeutics?
What are the different initiatives undertaken by big pharma players for the development of next generation complement therapeutics in the recent past?
How is the current and future market opportunity, related to next generation complement therapeutics likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the next generation complement therapeutics market in the mid to long term.

Chapter 3 provides a general overview of complement system including information on the immune cells involved in complement system, and sources of key complement proteins. In addition, the chapter presents details on the complement activation pathways (classical, lectin, alternative and terminal pathway). It also features information on consequences of a dysregulated complement system, types of complement therapeutics, limitations and future of next generation complement therapeutics.

Chapter 4 provides an overview of the current market landscape of next generation complement therapeutics, based on several relevant parameters, such as status of development (marketed, phase III, phase II / III, phase II, phase I / II, phase I, and preclinical stage), type of molecule (biologic and small molecule), biological target, target pathway (alternative, classical, lectin and terminal pathway), mechanism of action, target disease indication(s), therapeutic area(s), route of administration (intrarenal, intravenous, intravitreal, nasal, oral and subcutaneous) and type of therapy (monotherapy and combination therapy).

Chapter 5 includes detailed profiles of key players engaged in the development of next generation complement therapeutics. Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.

Chapter 6 provides information on more than 870 completed, ongoing and planned clinical studies of next generation complement therapeutics, based on different parameters, such as trial status, trial registration year, trial phase, enrolled patient population, type of sponsor / collaborator, type of study, and study design. In addition, the chapter highlights leading industry and non-industry players, key indication(s), popular therapeutics area(s), type of drug, emerging focus areas and regional distribution of trials.

Chapter 7 features a detailed review of more than 1,450 peer-reviewed, scientific articles related to research on next generation complement therapeutics, based on parameters, such as year of publication, emerging focus area, top authors, key research journals, popular indication(s) and therapeutic area(s) (in terms of number of articles published).

Chapter 8 provides an in-depth analysis of grants that have been awarded to various research institutes for projects related to next generation complement therapeutics, during 2017-2021, on the basis of important parameters, such as year of grant awarded, amount awarded, funding institute center, support period, type of grant, activity code, while highlighting popular recipient organizations (in terms of number and amount of grants awarded), popular NIH departments, study section. The chapter also highlights type of recipient organization, emerging focus areas of the grants, purpose of grant awarded, prominent program officers and location of recipient organizations.

Chapter 9 features an in-depth analysis of the patents that have been filed / granted for next generation complement therapeutics, between 2016-2021, on the basis of various relevant parameters, such as patent publication year, type of patent, geographical location, CPC symbols, type of applicant, patent age, emerging focus areas, leading industry and non-industry players (in terms of number of patents granted / filed) and patent characteristics. In addition, it includes detailed patent benchmarking and an insightful valuation analysis.

Chapter 10 features an analysis of the partnerships that have been established in this domain, covering instances of clinical trials agreement, distribution and supply agreement, licensing agreement, product development and commercialization agreement, product development and manufacturing agreement, research and development agreements and other relevant types of deals.

Chapter 11 presents detailed analysis of various funding and investments made since 2014, including venture capital financing, secondary offering, private placement, grant, debt financing and other equity in the companies focused on the development of next generation complement therapeutics.

Chapter 12 includes an analysis of big pharma players engaged in the field of next generation complement therapeutics, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on several relevant parameters, such as number of therapeutics under development, type of molecule, status of development, number of therapeutic areas, number of partnerships, number of patents and years of experience.

Chapter 13 presents an insightful market forecast analysis, highlighting the future potential of the next generation complement therapeutics market till the year 2035. It includes future sales projections of next generation complement therapeutics that are either marketed or are likely to be marketed within the next two years. In order to provide a detailed future outlook, our projections have been segmented across (A) Target Disease Indications (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), (B) Therapeutic Areas (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), (C) Type of Molecule (Biologics and Small Molecules), (D) Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), (E) Type of Therapy (Monotherapy and Combination Therapy), (F) Route of Administration (Intravenous, Oral and Subcutaneous), and (G) Key Geographical Regions (North America, Europe and Asia-Pacific).

Chapter 14 presents expert opinion in the complement therapeutics domain.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES / LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.

1. AbbVie
2. Achillion Pharmaceuticals (acquired by Alexion Pharmaceuticals)
3. Adage Capital Management
4. ADIENNE
5. Adverum Biotechnologies
6. AffaMed Therapeutics
7. AJU IB Investment
8. Akari Therapeutics
9. Alexion Pharmaceuticals
10. Ally Bridge
11. Alnylam Pharmaceuticals
12. Alsonex
13. Amgen
14. Amyndas Pharmaceuticals
15. Annexon Biosciences
16. Apellis Pharmaceuticals
17. Aquilo Capital
18. argenx
19. Assistance Publique - Hôpitaux de Paris (AP-HP)
20. AstraZeneca
21. Athyrium Capital Management
22. Attune Pharmaceuticals
23. Bain Capital Life Sciences
24. Bayer
25. Beam Therapeutics
26. BioCryst Pharmaceuticals
27. Biogen
28. BioMarin Pharmaceutical
29. Bioverativ (acquired by Sanofi)
30. BlackRock
31. Blackstone Life Sciences (BXLS)
32. Boston University Medical Campus (BUMC)
33. Boxer Capital
34. Bristol Myers Squibb
35. Broad Institute
36. Broteio Pharma
37. Burrage Capital Management
38. Camurus
39. CANbridge Pharmaceuticals
40. Catalyst Biosciences
41. Center for Research on Inflammatory Diseases (CRID)
42. ChemoCentryx
43. China Life Private Equity Investment
44. Chugai Pharmaceutical
45. Cincinnati Children's Hospital Medical Center
46. Clarus (acquired by Blackstone)
47. Clinigen
48. Clough Capital Partners
49. Columbia University Health Sciences
50. Complement Pharma
51. Cormorant Asset Management
52. Correlation Ventures
53. CRG Capital Partners
54. CSL Behring
55. CVie Therapeutics
56. DAFNA Capital Management
57. Deerfield Management
58. Dicerna Pharmaceuticals
59. Dompé Pharmaceuticals
60. Duke University
61. Dyax (acquired by Shire)
62. East West Bank
63. Epidarex Capital
64. Eventide Asset Management
65. Farallon Capital Management
66. Federal Ministry of Education and Research (Germany)
67. Federal Ministry of Health (Germany)
68. Foresite Capital
69. F-Prime Capital Partners
70. Frazier Life Sciences
71. Future Industry Investment Fund
72. Genentech
73. GENERIUM
74. Genzyme (a subsidiary of Sanofi)
75. GlaxoSmithKline
76. Halozyme Therapeutics
77. Harvard College
78. Hemera Biosciences
79. Hercules Capital
80. Hillhouse Capital
81. Icahn School of Medicine at Mount Sinai (ISMMS)
82. I-Mab
83. InflaRx
84. Innate Pharma
85. Innovent Biologics
86. Ionis Pharmaceuticals
87. IQVIA
88. ISU ABXIS
89. Iveric Bio
90. Janus Henderson Investors
91. Johns Hopkins University
92. KalVista Pharmaceuticals
93. Karolinska Institutet
94. Kissei Pharmaceutical
95. Legend Capital
96. LifeSci Venture Partners
97. Lilly Asia Ventures
98. Logos Capital
99. Longwood Fund
100. Mallinckrodt
101. Massachusetts General Hospital
102. MidCap Financial
103. Milestone Capital Advisors
104. Morningside Ventures
105. MorphoSys
106. MPM Capital
107. National Cancer Institute (NCI)
108. National Institute of Allergy and Infectious Diseases (NIAID)
109. National Institute of Mental Health (NIMH)
110. National Institutes of Health Clinical Center (NIHCC)
111. Neopharm
112. New Enterprise Associates (NEA)
113. NewBridge Pharmaceuticals
114. Nichi-Iko Pharmaceutical
115. Novartis
116. Novartis Venture Fund
117. NovelMed Therapeutics
118. Novo
119. NOXXON Pharma
120. NYU Grossman School of Medicine
121. Omeros
122. OMERS
123. OrbiMed Advisors
124. Oxford Finance
125. PANTHERx
126. Parexel
127. Paulson Investment
128. Perceptive Advisors
129. Pharmasyntez
130. Pharming
131. Ping An
132. Prothix
133. Qiming Venture Partners
134. Quartesian
135. QVT Financial
136. RA Capital Management
137. Ra Pharmaceuticals (acquired by UCB)
138. Redmile
139. Regeneron
140. Regenesance
141. Roche
142. Rock Springs Capital
143. Royalty Pharma
144. RPC Pharma
145. RTW Investments
146. Samsung Bioepis
147. Sanofi
148. Satter Investment Management
149. Satter Medical Technology Partners
150. Sectoral Asset Management
151. Selexis
152. SFJ Pharmaceuticals
153. Shire (acquired by Takeda)
154. Silence Therapeutics
155. Sobi
156. Sofinnova
157. Staidson Hongkong Investment
158. Stanford University
159. Surveyor Capital
160. SV Life Sciences
161. Taikang Insurance
162. Takeda
163. Tang Capital Management
164. Tasly Biopharmaceuticals
165. Temasek
166. TF Capital
167. Torii Pharmaceutical
168. UCB
169. UC San Diego
170. University of California, San Francisco
171. University of Cambridge
172. University of Colorado
173. University of Leicester
174. University of Michigan
175. University of North Carolina at Chapel Hill
176. University of Pennsylvania
177. University of Pittsburgh
178. venBio Global Strategic Fund
179. venBio Select
180. Venrock
181. Vifor Pharma
182. Vivo Capital
183. Washington University
184. WuXi Biologics
185. Xencor
186. Yale University
187. Zealand Pharma


Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.